Mabion Holds Pre-IND Meeting With FDA
Mabion SA announced it has held a Pre-IND Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the development of MabionCD20 for the treatment of Immune Thrombocytopenia (ITP).
Mabion SA announced it has held a Pre-IND Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the development of MabionCD20 for the treatment of Immune Thrombocytopenia (ITP).